Aa
Has anyone invested in Vertex stock?
Was wondering if now is a good time to buy Vertex stock. After seeing that Telaprevir brought my 10 million VL to UNDE at 20 days I feel compelled to buy their stock. Kind of like my own inside information ;-) I have never bought stock before and this will be the only time.
Good to see you posting again.
I am doing well except for the insomnia - partly caused by the economy - LOL. The Vertex dropouts will be substantially mitigated by rescue drugs that have not been allowed in the trials. Most of the dropouts are due to anemia. I bought in at 16 and have not sold anything yet.
Let's hope Obama succeeds. If he doesn't we are toast!
I am doing well except for the insomnia - partly caused by the economy - LOL. The Vertex dropouts will be substantially mitigated by rescue drugs that have not been allowed in the trials. Most of the dropouts are due to anemia. I bought in at 16 and have not sold anything yet.
Let's hope Obama succeeds. If he doesn't we are toast!
Hello Eric...let's get to the important stuff first, how are you feeling? I saw your post regarding insomnia...ditto here. although I admit, I have been more than prone to insomnia since giving up the sauce some 15 years ago...;^)
Obviously can't argue the diversification point, common sense after all.
Obamer (accent Bernie and Phil's furniture in Boston(lol) has been making some pretty decent choices so far, although I worry he might tap into the old Clinton guard to deeply (we'll see)..
I think one can double on chk before vrtx on a much better risk reward basis...Good luck with SSO,,,and leverage..I like your thinking...I hope you are right....
My idea to further boost the economy....raise the 2008 capital tax loss writeoff limit, effective immediately.......
12 degrees here this morning with a stiff wind, I heat with wood, not ng...;^)pro
We'll revisit the vrtx discussion down the road, I believe there is no hurry to get in, still a lot of burn rate time pass between now and chance of fda approval..
Obviously can't argue the diversification point, common sense after all.
Obamer (accent Bernie and Phil's furniture in Boston(lol) has been making some pretty decent choices so far, although I worry he might tap into the old Clinton guard to deeply (we'll see)..
I think one can double on chk before vrtx on a much better risk reward basis...Good luck with SSO,,,and leverage..I like your thinking...I hope you are right....
My idea to further boost the economy....raise the 2008 capital tax loss writeoff limit, effective immediately.......
12 degrees here this morning with a stiff wind, I heat with wood, not ng...;^)pro
We'll revisit the vrtx discussion down the road, I believe there is no hurry to get in, still a lot of burn rate time pass between now and chance of fda approval..
Good News, Bad News For Vertex’s Telaprevir (VX-950)
Syndicated from Envisioning 2.0 by fardj | Fri, 11/02/2007 - 10:42am | original article
post a comment | comments (0)
As readers of this blog are aware, I’ve been following the progress of Vertex’s hepatitis C drug (Telaprevir or VX-950 ) over the past year or so. I initially wrote about it from a communications perspective, saying that the drug was promising. However, there were signs that company leadership may have overstated its potential.
Today, we learn why it is always a good idea to exercise caution when communicating about a drug early on. According to Reuters:
“Vertex Pharmaceuticals Inc (VRTX.O: Quote, Profile, Research) released data on Friday showing its experimental hepatitis C drug is more effective than existing treatments and works in half the time, but causes significantly more side effects.”
The side effect issue is a big deal. In one Vertex trial, PROVE 1, 13% of patients stopped taking the drug in the first 12 weeks of the study because of side effects. In addition, “65 percent of patients who took part in the 24-week treatment regime . . . saw the virus eradicated and stay eradicated after three months.”
The results were a disappointment to investors who sent Vertex stock tumbling. Vertex’s product becomes a much tougher sell because its efficacy profile may not be enough to overcome its toxicity. If patients are not continuing therapy because of side effects, physicians will be less likely to prescribe it to patients. This is especially true if there is another – equally effective – therapy with fewer adverse events.
Now we wait for the FDA’s decision on the drug. Observers think it will be approved, but we’ll see how physicians react once it is on the market.
Syndicated from Envisioning 2.0 by fardj | Fri, 11/02/2007 - 10:42am | original article
post a comment | comments (0)
As readers of this blog are aware, I’ve been following the progress of Vertex’s hepatitis C drug (Telaprevir or VX-950 ) over the past year or so. I initially wrote about it from a communications perspective, saying that the drug was promising. However, there were signs that company leadership may have overstated its potential.
Today, we learn why it is always a good idea to exercise caution when communicating about a drug early on. According to Reuters:
“Vertex Pharmaceuticals Inc (VRTX.O: Quote, Profile, Research) released data on Friday showing its experimental hepatitis C drug is more effective than existing treatments and works in half the time, but causes significantly more side effects.”
The side effect issue is a big deal. In one Vertex trial, PROVE 1, 13% of patients stopped taking the drug in the first 12 weeks of the study because of side effects. In addition, “65 percent of patients who took part in the 24-week treatment regime . . . saw the virus eradicated and stay eradicated after three months.”
The results were a disappointment to investors who sent Vertex stock tumbling. Vertex’s product becomes a much tougher sell because its efficacy profile may not be enough to overcome its toxicity. If patients are not continuing therapy because of side effects, physicians will be less likely to prescribe it to patients. This is especially true if there is another – equally effective – therapy with fewer adverse events.
Now we wait for the FDA’s decision on the drug. Observers think it will be approved, but we’ll see how physicians react once it is on the market.
While many stocks are good buys today, a prudent investor should spread the investment portfolio into as many different sectors as possible. The biotech sector is getting killed due to the financial crisis: people are afraid that companies will not be able to get the money to bring products through the costly stage of human testing.
Vertex is in the final stage of that, but is beaten down. Personally, I think it will get approval by 2010 and will more than double. Just my guess though.
The market will be overjoyed by Obama's financial team and will take off on Monday - just another guess though. I will by SSO - an ETF that will double the movement of the S&P 500.
Vertex is in the final stage of that, but is beaten down. Personally, I think it will get approval by 2010 and will more than double. Just my guess though.
The market will be overjoyed by Obama's financial team and will take off on Monday - just another guess though. I will by SSO - an ETF that will double the movement of the S&P 500.
I can understand the emotional attachment, but would have to question why someone would want to swim in the biotech ocean now? There are so many other stocks out there selling at cheap valuations...Where will Vertex be in a years time?......................and where will, let's say, Chesapeake Energy (CHK) be? My money is on CHK $15.44/sh.
...pro
...pro
There are so many small pharma companies, with so many products in the pipeline out there. It's a bit like investinig in oil exploration - most of them are "home run" or "bust" proposition. The trials still out on Vertex, the big question is how it will shape up against all the other competitors out there, many of which don't have a "rash". We won't know that for a few years.
Interesting to read about the early stage trials on competing antivirals without inteferon:
http://www.hepatitis-central.com/mt/archives/2008/11/new_hcv_trial_c.html?eml=hepcen66
Interesting to read about the early stage trials on competing antivirals without inteferon:
http://www.hepatitis-central.com/mt/archives/2008/11/new_hcv_trial_c.html?eml=hepcen66
Many analysts think the stock will reach $45 once Telaprevir gets approved.
Conditions are so bad in the overall market that even good stocks are going down.
Conditions are so bad in the overall market that even good stocks are going down.
I bought a hundred shares when it was at 33, so I sure hope it returns to that price and then goes on up from there. If I'd had a few bucks to play with I'd have bought another hundred shares when it got into the teens, but I didn't so I couldn't. Oh well...
I still have high hopes for this stock. However, my broker says the company is overextended financially, which could cause problems. Vertex has gone up to 40 in the past - so I'm waiting for the drug's release and sitting on this one.
Geterdone, you certainly got her done. Buy low, sell high - great timing!
pigeon
I still have high hopes for this stock. However, my broker says the company is overextended financially, which could cause problems. Vertex has gone up to 40 in the past - so I'm waiting for the drug's release and sitting on this one.
Geterdone, you certainly got her done. Buy low, sell high - great timing!
pigeon
Yeah, I thank Jim to for pounding away on the telaprevir trials and the benefits of telaprevir itself and research presented, but unfortunately Jim will not receive the same in the way of monetary value of the benefits I had received from his constant pounding : ). If my memory serves me correctly, I spoke out against telaprevir on its time line to market but did eventually start following it as an investment vehicle and surprised myself and bought a couple of shares while treating but glad I did, boy what a leap of faith that was, lol.
jasper
jasper
I did because I believed in the drug. I didn't go big into it but enough that I feel involved. Mike
Tough call, I bought vertex at 19 thinking it was a good buy but then 2 weeks later it went down to 15 and hesitated to buy more because of the competitions compelling reports at the time. Kicked my self in the butt at the time because it turned into a strong upward swing and went to 34.48 a share and that is where I sold it at. I am sitting on the side lines waiting for it to drop again but it looks like it has built a floor at its present price which is very encouraging considering this down market. The market seems to be tolerating its last quarterly losses based on the assumption that the vertex trials will bare more fruit going forward. I can only hope that it will drop back to 19 again on some insignificant bad news. The bios have been pretty resistant from the collateral damage of the markets thus far but are not immune from an infection so there may be an opportunity when this happens.
jasper
jasper
Have an Answer?
You are reading content posted in the Hepatitis Social Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
